Monday, November 17, 2025 11/17/2025

Genetic and molecular basis of hematopoietic abnormalities in ZTTK syndrome

Award Number: R01HL168659
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/15/2023
PERIOD OF PERFORMANCE END DATE: 12/31/2026

Group Awards By:

View Award Description

Genetic and molecular basis of hematopoietic abnormalities in ZTTK syndrome - PROJECT SUMMARY Individuals with rare genetic diseases do not receive attention from the medical and research community. One out of two patients diagnosed with a rare disease is a child, meaning that patients and their families must endure long battles relating to disease progress throughout their child’s lifetime. Therefore, characterization of clinical/molecular aspects of rare diseases will greatly benefit young patients and their families. SON is a DNA- and RNA-binding protein that plays dual roles as an RNA splicing factor and a transcriptional repressor. Our research team recently identified Zhu-Tokita-Takenouchi-Kim syndrome (ZTTK syndrome), a rare genetic disease with multi-organ abnormalities caused by heterozygous loss-of-function mutations in the SON gene (SON haploinsufficiency). Our research and publication played a key role in documenting this syndrome in major public databases to facilitate clinical diagnosis. As a first step in supporting ZTTK families and promoting awareness, we recently launched an official foundation, the ZTTK SON-Shine Foundation. Our recent efforts revealed that many children with ZTTK syndrome experience various hematopoietic disorders and immune dysfunction, which sometimes leads to life-threatening sepsis. To understand the hematopoietic abnormalities associated with ZTTK syndrome, we have generated mouse models of Son knockout (KO) and Son haploinsufficiency. Our preliminary data demonstrated that complete Son KO in hematopoietic cells causes hematopoietic stem cell (HSC) expansion and embryonic lethality. Furthermore, we found that Son haploinsufficiency leads to abnormal proportions of lineage-primed multipotent progenitors (MPPs), with an expansion of megakaryocyte-erythroid lineage-primed MPPs and a shrinkage of lymphoid lineage-primed MPPs, which is already evident during fetal liver hematopoiesis and persists in adult hematopoiesis in the bone marrow. Importantly, our RNA-sequencing analyses revealed that critical chromatin modifier genes were the major targets dysregulated by Son haploinsufficiency in early stage hematopoietic stem and progenitor cells (HSPCs). Based on these preliminary data, our central hypothesis is that Son haploinsufficiency directly and indirectly alters the expression/splicing of key chromatin modifiers, which collectively reshapes chromatin status at the level of HSCs and MPPs, and this leads to skewed lineage bias and impaired functional output of HSCs/MPPs. To test these hypotheses, we will investigate how Son haploinsufficiency affects functional output of HSCs and lineage primed MPPs in vivo (Aim 1), and will dissect the underlying molecular mechanisms by which Son haploinsufficiency leads to HSPC abnormalities (Aim 2). Successful completion of this proposed study will significantly advance our knowledge about ZTTK syndrome-associated abnormal hematological features and will serve as a valuable resource to identify therapeutic strategies. Most importantly, this study will bring hope to children and their families battling this rare disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $519,177 )
2025	2025	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Blood Diseases and Resources Research	000	3	12/27/2024	NON-COMPETING CONTINUATION	$467,259
2025	2025	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Blood Diseases and Resources Research	001	3	8/19/2025	NON-COMPETING CONTINUATION	$51,918
														Subtotal = $519,177

Issue Date FY: 2024 ( Subtotal = $508,794 )
2024	2024	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Blood Diseases and Resources Research	000	2	12/11/2023	NON-COMPETING CONTINUATION	$467,259
2024	2024	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Blood Diseases and Resources Research	001	2	6/22/2024	NON-COMPETING CONTINUATION	$41,535
														Subtotal = $508,794

Issue Date FY: 2023 ( Subtotal = $519,177 )
2023	2023	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Blood Diseases and Resources Research	000	1	3/14/2023	NEW	$519,177
														Subtotal = $519,177

Grand Total All Awards = $1,547,148

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Genetic and molecular basis of hematopoietic abnormalities in ZTTK syndrome

Award Number: R01HL168659

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/15/2023

PERIOD OF PERFORMANCE END DATE: 12/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer